Program
cadonilimab
Also written as “AK104”, “Cadonilimab” and “Cadonilimab (AK104)”.
Its studies are mostly in Carcinoma, Hepatocellular · Carcinoma, Non-Small-Cell Lung · Uterine Cervical Neoplasms · Carcinoma, Renal Cell · Stomach Neoplasms, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Akeso | 4219 open or running | phase 3since Jul 21, 2021 | Aug 20, 2017 | Nov 2026phase 3 · NCT06341335 |
| RemeGen | 11 open or running | phase 3since Jan 15, 2024 | Jan 15, 2024 | Dec 2026phase 3 · NCT06221748 |
| Shanghai Pharmaceuticals | 11 open or running | phase 2since Jul 6, 2023 | Jul 6, 2023 | Dec 31, 2026phase 2 · NCT05944224 |
| Summit Therapeutics | 11 open or running | phase 2since Sep 29, 2026 | Sep 29, 2026 | Apr 12, 2029phase 2 · NCT07877194 |
Also a collaborator on its studies: Chipscreen Biosciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 32 studies since Aug 20, 2017.
- Mar 26, 2024Phase 3 study in Gastric and Gastroesophageal Junction AdenocarcinomaAkeso · NCT06341335 · 506 planned · China
- Apr 15, 2024Phase 3 study in Carcinoma, HepatocellularAkeso · NCT06371157 · 469 planned · China
- Aug 15, 2024Phase 2 study in Ovarian NeoplasmsAkeso · NCT06560112 · 172 planned · China
- Sep 25, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungAkeso · NCT06617416 · 560 planned · China
- Oct 16, 2024Phase 2 study in Metastatic Pancreatic Ductal AdenocarcinomaAkeso · NCT06646055 · 110 enrolled · China
- May 15, 2025Phase 2 study in Carcinoma, HepatocellularAkeso · NCT06984718 · 120 planned
- Jun 10, 2025Phase 3 study in AdenocarcinomaAkeso · NCT07023315 · 760 planned · China
- Nov 24, 2025Phase 2 study in Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaAkeso · NCT07263919 · 90 planned · China
- Feb 9, 20262 phase 3 studiesAkeso · NCT07412613, NCT07449780
- May 26, 2026Phase 1 study in Healthy Male Adults ParticipantsAkeso · NCT07619001 · 158 planned · China
- Jul 8, 2026Phase 3 study in Stomach NeoplasmsAkeso · NCT07700979 · 900 planned · United States, China, Germany and more
- Sep 28, 2026Phase 2 study terminatedStudy stoppedNCT05932212 · “Sponsor decision”
- Sep 29, 2026Summit Therapeutics's first study: phase 2 study in Carcinoma, Renal CellNew to Summit TherapeuticsSummit Therapeutics · NCT07877194 · 100 planned · United States, China
- Nov 12, 2026Primary completion moved from 2026-11-05 to 2028-06-30Date moved laterphase 1 · +20 months · NCT06929663
Ahead
- Nov 2026Primary completion: phase 3 study in Gastric and Gastroesophageal Junction AdenocarcinomaAkeso · NCT06341335
- Nov 30, 2026Primary completion: phase 2 study in Carcinoma, HepatocellularAkeso · NCT06984718
- Dec 2026Primary completion: phase 3 study in Stomach NeoplasmsRemeGen · NCT06221748
- Dec 30, 2026Primary completion: phase 2 study in Metastatic Pancreatic Ductal AdenocarcinomaAkeso · NCT06646055
TargetBeta
“A bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), ”NCIt, by rule
“Programmed cell death protein 1 inhibitor; Cytotoxic T-lymphocyte protein 4 inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| lorigerlimabrule | MacroGenics | phase 2 | 4 |
| Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rule | hc-biopharma-inc | phase 2 | 2 |
Studies
All 45 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07877194Carcinoma, Renal Cell · United States, China | 2 | Not yet recruiting | Summit Therapeutics | Apr 12, 2029 | 100 |
| NCT07700979Stomach Neoplasms · United States, China, Germany and more | 3 | Recruiting | Akeso | Aug 18, 2029 | 900 |
| NCT07619001Healthy Male Adults Participants · China | 1 | Not yet recruiting | Akeso | Sep 30, 2026 | 158 |
| NCT07449780Gastric / Gastroesophageal Junction Adenocarcinoma | 3 | Not yet recruiting | Akeso | Nov 17, 2027 | 422 |
| NCT07412613Resectable Colon Cancer · China | 3 | Recruiting | Akeso | Jun 15, 2030 | 386 |
| NCT07263919Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma · China | 2 | Recruiting | Akeso | Mar 2030 | 90 |
| NCT07023315Adenocarcinoma · China | 3 | Recruiting | Akeso | Jul 2029 | 760 |
| NCT06984718Carcinoma, Hepatocellular | 2 | Not yet recruiting | Akeso | Nov 30, 2026 | 120 |
| NCT06646055Metastatic Pancreatic Ductal Adenocarcinoma · China | 2 | Active, not recruiting | Akeso | Dec 30, 2026 | 110 |
| NCT06617416Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Akeso | Oct 28, 2026 | 560 |
| NCT06560112Ovarian Neoplasms · China | 2 | Recruiting | Akeso | May 1, 2026 | 172 |
| NCT06371157Carcinoma, Hepatocellular · China | 3 | Recruiting | Akeso | Oct 25, 2025 | 469 |
| NCT06341335Gastric and Gastroesophageal Junction Adenocarcinoma · China | 3 | Recruiting | Akeso | Nov 2026 | 506 |
| NCT06221748Stomach Neoplasms · China | 3 | Recruiting | RemeGen | Dec 2026 | 90 |
| NCT05990127Carcinoma, Non-Small-Cell Lung · China | 3 | Not yet recruiting | Akeso | Aug 5, 2025 | 642 |
| NCT05944224Advanced Solid Tumors · China | 2 | Recruiting | Shanghai Pharmaceuticals | Dec 31, 2026 | 63 |
| NCT05932212Vulvar Neoplasms · China | 2 | Terminated | Akeso | May 31, 2026 | 20 |
| NCT05904379Advanced Non-small-cell Lung Cancer · China | 2 | Active, not recruiting | Akeso | Jun 30, 2026 | 233 |
| NCT05559554Healthy Male Subjects · China | 1 | Completed | Akeso | Mar 24, 2023 | 100 |
| NCT05559541Solid Tumor, Adult · China | 2 | Terminated | Akeso | May 31, 2024 | 33 |
| NCT05505825SCLC,Extensive Stage · Australia, China | 2 | Completed | Akeso | Jul 19, 2024 | 36 |
| NCT05489289Carcinoma, Hepatocellular · China | 3 | Recruiting | Akeso | Jan 28, 2026 | 570 |
| NCT05319431Unresectable, Non-metastatic Hepatocellular Carcinoma · China | 2 | Active, not recruiting | Akeso | Aug 15, 2023 | 60 |
| NCT05227651Uterine Cervical Neoplasms · China | 2 | Completed | Akeso | Sep 27, 2024 | 14 |
| NCT05235542Advanced Malignant Tumors · China | 2 | Completed | Akeso | May 9, 2026 | 128 |
| NCT05256472Carcinoma, Renal Cell · China | 2 | Completed | Akeso | Dec 31, 2025 | 28 |
| NCT05235516Locally Advanced Cervical Carcinoma · China | 3 | Active, not recruiting | Akeso | May 2026 | 636 |
| NCT05215067Advanced Non-small Cell Lung Cancer · China | 2 | Completed | Akeso | Jan 30, 2026 | 44 |
| NCT05142423Advanced Solid Tumor · China | 2 | Recruiting | Akeso | Apr 2027 | 198 |
| NCT05021120Advanced or Metastatic Solid Tumours · Australia | Early 1 | Completed | Akeso | Oct 1, 2024 | 67 |
| NCT05008783Gastric Adenocarcinoma · China | 3 | Completed | Akeso | Dec 6, 2024 | 610 |
| NCT04982237Uterine Cervical Neoplasms · China | 3 | Active, not recruiting | Akeso | Dec 30, 2025 | 445 |
| NCT04868708Recurrence · China | 2 | Completed | Akeso | Feb 28, 2024 | 50 |
| NCT04728321Carcinoma, Hepatocellular · China | 2 | Completed | Akeso | Aug 2, 2022 | 32 |
| NCT04646330NSCLC · China | 2 | Completed | Akeso | Oct 26, 2023 | 114 |
| NCT04647344Lung Cancer Non-Small Cell Stage IIIB/IIIC/IV · China | 2 | Completed | Akeso | Dec 31, 2023 | 46 |
| NCT04572152Advanced or Metastatic Solid Tumors · Australia | 1 | Completed | Akeso | May 2, 2023 | 23 |
| NCT04547101MSI-H/dMMR Solid Tumor · China | 2 | Terminated | Akeso | Sep 30, 2022 | 6 |
| NCT04444167Carcinoma, Hepatocellular · China | 2 | Completed | Akeso | Nov 20, 2023 | 59 |
| NCT04444141Lymphoma, T-Cell, Peripheral · China | 2 | Terminated | Akeso | Sep 30, 2022 | 6 |
| NCT04380805Uterine Cervical Neoplasms · United States, Australia, New Zealand | 2 | Completed | Akeso | Dec 22, 2022 | 30 |
| NCT04220307Nasopharyngeal Carcinoma · China | 2 | Completed | Akeso | May 15, 2021 | 34 |
| NCT04172454Melanoma · China | 2 | Completed | Akeso | Jun 17, 2021 | 68 |
| NCT03852251Diabetes Mellitus, Insulin-Dependent, 12 · China | 2 | Completed | Akeso | Mar 25, 2024 | 338 |
| NCT03261011Advanced Cancer · Australia | 1 | Completed | Akeso | Aug 27, 2021 | 119 |
How it is read
Names in the registry
- “AK104”, 26 entries
- “Cadonilimab”, 3 entries
- “Cadonilimab (AK104)”, 3 entries
- “AK112, Cadonilimab, nab-paclitaxel, gemcitabine”, 3 entries
- “AK104+anlotinib”, 3 entries
Codes read as this program: AK104.
Conditions, from the studies’ own filings
- Carcinoma, Hepatocellular, 6 studies
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Uterine Cervical Neoplasms, 4 studies
- Carcinoma, Renal Cell, 2 studies
- Stomach Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.